# Figure 1




Figure 1: Competitive inhibition of $^{111}$In labelled 1033-trastuzumab binding to SKBR-3 cells by cold (unlabelled, without 1033-conjugate) trastuzumab.

# Figure 2




Figure 2: Comparison of whole body clearance of radioactivity in rats injected with $^{111}$In-1033-trastuzumab (filled triangles) or $^{111}$In-1033-rituximab (filled squares) antibody conjugates expressed as percentage ± std.dev. The data are corrected for radioactivity decay and background.

# Figure 3




Figure 3: Comparison of whole blood clearance of radioactivity in rats, injected with $^{111}$In-1033-trastuzumab (filled triangles) or $^{111}$In-1033-rituximab (filled squares) antibody conjugates, expressed as % of activity at start ± std.dev. The data are corrected for radioactivity decay.

# Figure 4




Figure 4: Biodistribution of $^{111}$In-1033-trastuzumab in rats, expressed as % of injected dose per gram tissue ± std.dev. The results are corrected for radiochemical decay.

# Figure 5




Figure 5: Biodistribution of $^{111}$In-1033-rituximab in rats, expressed as % of injected dose per gram tissue ± std.dev. The results are corrected for radiochemical decay.